vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and FIRSTSUN CAPITAL BANCORP (FSUN). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $110.0M, roughly 1.8× FIRSTSUN CAPITAL BANCORP). FIRSTSUN CAPITAL BANCORP runs the higher net margin — 19.6% vs -14.6%, a 34.2% gap on every dollar of revenue. Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 6.9%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
FirstSun Capital Bancorp is a U.S.-headquartered financial holding company that offers a comprehensive range of banking and financial services, including commercial and consumer lending, deposit products, wealth management, and treasury solutions. It mainly serves individual customers, small and medium-sized enterprises, and corporate clients across U.S. regional markets.
AXSM vs FSUN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $110.0M |
| Net Profit | $-28.6M | $21.6M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | — |
| Net Margin | -14.6% | 19.6% |
| Revenue YoY | 65.0% | — |
| Net Profit YoY | 61.9% | -8.4% |
| EPS (diluted) | $-0.55 | $0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $110.0M | ||
| Q4 25 | $196.0M | $110.2M | ||
| Q3 25 | $171.0M | $107.3M | ||
| Q2 25 | $150.0M | $105.6M | ||
| Q1 25 | $121.5M | $96.2M | ||
| Q4 24 | $118.8M | $98.7M | ||
| Q3 24 | $104.8M | $98.2M | ||
| Q2 24 | $87.2M | $96.2M |
| Q1 26 | — | $21.6M | ||
| Q4 25 | $-28.6M | $24.8M | ||
| Q3 25 | $-47.2M | $23.2M | ||
| Q2 25 | $-48.0M | $26.4M | ||
| Q1 25 | $-59.4M | $23.6M | ||
| Q4 24 | $-74.9M | $16.4M | ||
| Q3 24 | $-64.6M | $22.4M | ||
| Q2 24 | $-79.3M | $24.6M |
| Q1 26 | — | — | ||
| Q4 25 | -13.8% | 29.0% | ||
| Q3 25 | -27.0% | 26.4% | ||
| Q2 25 | -24.5% | 31.2% | ||
| Q1 25 | -46.9% | 30.9% | ||
| Q4 24 | -61.1% | 20.4% | ||
| Q3 24 | -59.8% | 29.1% | ||
| Q2 24 | -89.5% | 32.3% |
| Q1 26 | — | 19.6% | ||
| Q4 25 | -14.6% | 22.5% | ||
| Q3 25 | -27.6% | 21.6% | ||
| Q2 25 | -32.0% | 25.0% | ||
| Q1 25 | -48.9% | 24.5% | ||
| Q4 24 | -63.1% | 16.6% | ||
| Q3 24 | -61.7% | 22.8% | ||
| Q2 24 | -91.0% | 25.5% |
| Q1 26 | — | $0.76 | ||
| Q4 25 | $-0.55 | $0.89 | ||
| Q3 25 | $-0.94 | $0.82 | ||
| Q2 25 | $-0.97 | $0.93 | ||
| Q1 25 | $-1.22 | $0.83 | ||
| Q4 24 | $-1.54 | $0.57 | ||
| Q3 24 | $-1.34 | $0.79 | ||
| Q2 24 | $-1.67 | $0.88 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $413.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $1.2B |
| Total Assets | $689.8M | $8.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $413.7M | ||
| Q4 25 | $322.9M | $652.6M | ||
| Q3 25 | $325.3M | $659.9M | ||
| Q2 25 | $303.0M | $785.1M | ||
| Q1 25 | $300.9M | $621.4M | ||
| Q4 24 | $315.4M | $615.9M | ||
| Q3 24 | $327.3M | $573.7M | ||
| Q2 24 | $315.7M | $535.8M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $88.3M | $1.2B | ||
| Q3 25 | $73.7M | $1.1B | ||
| Q2 25 | $73.1M | $1.1B | ||
| Q1 25 | $53.2M | $1.1B | ||
| Q4 24 | $57.0M | $1.0B | ||
| Q3 24 | $92.9M | $1.0B | ||
| Q2 24 | $102.9M | $996.6M |
| Q1 26 | — | $8.6B | ||
| Q4 25 | $689.8M | $8.5B | ||
| Q3 25 | $669.3M | $8.5B | ||
| Q2 25 | $639.8M | $8.4B | ||
| Q1 25 | $596.7M | $8.2B | ||
| Q4 24 | $568.5M | $8.1B | ||
| Q3 24 | $561.5M | $8.1B | ||
| Q2 24 | $548.2M | $8.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | — |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $111.5M | ||
| Q3 25 | $1.0M | $49.4M | ||
| Q2 25 | $-32.4M | $15.0M | ||
| Q1 25 | $-43.4M | $26.4M | ||
| Q4 24 | $-26.2M | $101.1M | ||
| Q3 24 | $-18.6M | $48.1M | ||
| Q2 24 | $-30.1M | $20.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $104.0M | ||
| Q3 25 | $988.0K | $47.6M | ||
| Q2 25 | $-32.4M | $13.0M | ||
| Q1 25 | $-43.7M | $24.3M | ||
| Q4 24 | $-26.2M | $95.7M | ||
| Q3 24 | $-18.7M | $47.1M | ||
| Q2 24 | $-30.2M | $19.9M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 94.3% | ||
| Q3 25 | 0.6% | 44.4% | ||
| Q2 25 | -21.6% | 12.3% | ||
| Q1 25 | -36.0% | 25.3% | ||
| Q4 24 | -22.1% | 97.0% | ||
| Q3 24 | -17.9% | 47.9% | ||
| Q2 24 | -34.6% | 20.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 6.8% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.0% | 1.9% | ||
| Q1 25 | 0.3% | 2.1% | ||
| Q4 24 | 0.0% | 5.5% | ||
| Q3 24 | 0.1% | 1.1% | ||
| Q2 24 | 0.1% | 1.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.49× | ||
| Q3 25 | — | 2.13× | ||
| Q2 25 | — | 0.57× | ||
| Q1 25 | — | 1.12× | ||
| Q4 24 | — | 6.18× | ||
| Q3 24 | — | 2.15× | ||
| Q2 24 | — | 0.85× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
FSUN
| Net Interest Income | $82.8M | 75% |
| Noninterest Income | $27.2M | 25% |
